Dectin-1 activation by a natural product β-glucan converts immunosuppressive macrophages into an M1-like phenotype

Journal of Immunology

Volumn 195, Issue 10, 2015, Pages 5055-5065

  Liu, Min ^a,b   Luo, Fengling ^a,b   Ding, Chuanlin ^a   Albeituni, Sabrin ^c   Hu, Xiaoling ^a   Ma, Yunfeng ^a   Cai, Yihua ^a   McNally, Lacey ^a   Sanders, Mary Ann ^c   Jain, Dharamvir ^a   Kloecker, Goetz ^a   Bousamra, Michael ^c   Zhang, Huang Ge ^c   Higashi, Richard M ^d,e   Lane, Andrew N ^a,d,e   Fan, Teresa W M ^d,e   Yan, Jun ^a,c  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b WUHAN UNIVERSITY   (China)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CELL PROTEIN; DENTIN 1; GLUTAMINE; LECTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CARD9; PROTEIN KINASE SYK; UNCLASSIFIED DRUG; CARD9 PROTEIN, MOUSE; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; DECTIN 1; FUNGAL POLYSACCHARIDE; LECTIN;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL POLARITY; CELL TRANSFORMATION; CITRIC ACID CYCLE; CONTROLLED STUDY; DEPLETION; DRUG EFFICACY; DRUG MECHANISM; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; LEWIS CARCINOMA; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BETA-GLUCANS; CARD SIGNALING ADAPTOR PROTEINS; CELL LINE, TUMOR; FUNGAL POLYSACCHARIDES; LECTINS, C-TYPE; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; SACCHAROMYCES CEREVISIAE;

EID: 84958597853     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501158     Document Type: Article

References (52)

1. Mantovani, A. 2009. Cancer: Inflaming metastasis. Nature 457: 36-37.
2. Pollard, J. W. 2009. Trophic macrophages in development and disease. Nat. Rev. Immunol. 9: 259-270.
3. Ruffell, B., N. I. Affara, and L. M. Coussens. 2012. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33: 119-126.
4. Ganeshan, K., and A. Chawla. 2014. Metabolic regulation of immune responses. Annu. Rev. Immunol. 32: 609-634.
5. Qian, B. Z., and J. W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
6. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
7. Murray, P. J., J. E. Allen, S. K. Biswas, E. A. Fisher, D. W. Gilroy, S. Goerdt, S. Gordon, J. A. Hamilton, L. B. Ivashkiv, T. Lawrence, et al. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41: 14-20.
8. Bingle, L., N. J. Brown, and C. E. Lewis. 2002. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196: 254-265.
9. Campbell, M. J., N. Y. Tonlaar, E. R. Garwood, D. Huo, D. H. Moore, A. I. Khramtsov, A. Au, F. Baehner, Y. Chen, D. O. Malaka, et al. 2011. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res. Treat. 128: 703-711.
10. Dannenmann, S. R., J. Thielicke, M. Stöckli, C. Matter, L. von Boehmer, V. Cecconi, T. Hermanns, L. Hefermehl, P. Schraml, H. Moch, et al. 2013. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. OncoImmunology 2: e23562.
11. Chung, F. T., K. Y. Lee, C. W. Wang, C. C. Heh, Y. F. Chan, H. W. Chen, C. H. Kuo, P. H. Feng, T. Y. Lin, C. H. Wang, et al. 2012. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int. J. Cancer 131: E227-E235.
12. Wang, R., J. Zhang, S. Chen, M. Lu, X. Luo, S. Yao, S. Liu, Y. Qin, and H. Chen. 2011. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 74: 188-196.
13. De Palma, M., and C. E. Lewis. 2011. Cancer: Macrophages limit chemotherapy. Nature 472: 303-304.
14. DeNardo, D. G., D. J. Brennan, E. Rexhepaj, B. Ruffell, S. L. Shiao, S. F. Madden, W. M. Gallagher, N. Wadhwani, S. D. Keil, S. A. Junaid, et al. 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1: 54-67.
15. Ruffell, B., D. Chang-Strachan, V. Chan, A. Rosenbusch, C. M. Ho, N. Pryer, D. Daniel, E. S. Hwang, H. S. Rugo, and L. M. Coussens. 2014. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26: 623-637.
16. Liu, J., L. Gunn, R. Hansen, and J. Yan. 2009. Combined yeast-derived betaglucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp. Mol. Pathol. 86: 208-214.
17. Brown, G. D., J. Herre, D. L. Williams, J. A. Willment, A. S. Marshall, and S. Gordon. 2003. Dectin-1 mediates the biological effects of beta-glucans. J. Exp. Med. 197: 1119-1124.
18. Steele, C., L. Marrero, S. Swain, A. G. Harmsen, M. Zheng, G. D. Brown, S. Gordon, J. E. Shellito, and J. K. Kolls. 2003. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J. Exp. Med. 198: 1677-1688.
19. Gantner, B. N., R. M. Simmons, S. J. Canavera, S. Akira, and D. M. Underhill. 2003. Collaborative induction of inflammatory responses by dectin-1 and Tolllike receptor 2. J. Exp. Med. 197: 1107-1117.
20. Goodridge, H. S., A. J. Wolf, and D. M. Underhill. 2009. Beta-glucan recognition by the innate immune system. Immunol. Rev. 230: 38-50.
21. Goodridge, H. S., C. N. Reyes, C. A. Becker, T. R. Katsumoto, J. Ma, A. J. Wolf, N. Bose, A. S. Chan, A. S. Magee, M. E. Danielson, et al. 2011. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature 472: 471-475.
22. Elcombe, S. E., S. Naqvi, M. W. Van Den Bosch, K. F. MacKenzie, F. Cianfanelli, G. D. Brown, and J. S. Arthur. 2013. Dectin-1 regulates IL-10 production via a MSK1/2 and CREB dependent pathway and promotes the induction of regulatory macrophage markers. PLoS One 8: e60086.
23. Qi, C., Y. Cai, L. Gunn, C. Ding, B. Li, G. Kloecker, K. Qian, J. Vasilakos, S. Saijo, Y. Iwakura, et al. 2011. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived b-glucans. Blood 117: 6825-6836.
24. Wu, W., Y. M. Hsu, L. Bi, Z. Songyang, and X. Lin. 2009. CARD9 facilitates microbe-elicited production of reactive oxygen species by regulating the LyGDIRac1 complex. Nat. Immunol. 10: 1208-1214.
25. Le, A., A. N. Lane, M. Hamaker, S. Bose, A. Gouw, J. Barbi, T. Tsukamoto, C. J. Rojas, B. S. Slusher, H. Zhang, et al. 2012. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15: 110-121.
26. Ma, J., L. Liu, G. Che, N. Yu, F. Dai, and Z. You. 2010. The M1 form of tumorassociated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10: 112.
27. Heusinkveld, M., P. J. de Vos van Steenwijk, R. Goedemans, T. H. Ramwadhdoebe, A. Gorter, M. J. Welters, T. van Hall, and S. H. van der Burg. 2011. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 187: 1157-1165.
28. Krausgruber, T., K. Blazek, T. Smallie, S. Alzabin, H. Lockstone, N. Sahgal, T. Hussell, M. Feldmann, and I. A. Udalova. 2011. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 12: 231-238.
29. Sancho, D., and C. Reis e Sousa. 2012. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 30: 491-529.
30. Través, P. G., P. de Atauri, S. Marín, M. Pimentel-Santillana, J. C. Rodríguez-Prados, I. Marín de Mas, V. A. Selivanov, P. Martín-Sanz, L. Boscá, and M. Cascante. 2012. Relevance of the MEK/ERK signaling pathway in the metabolism of activated macrophages: a metabolomic approach. J. Immunol. 188: 1402-1410.
31. Fan, T. W., A. N. Lane, R. M. Higashi, M. A. Farag, H. Gao, M. Bousamra, and D. M. Miller. 2009. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 8: 41.
32. Fan, T. W., A. N. Lane, R. M. Higashi, and J. Yan. 2011. Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics 7: 257-269.
33. Movahedi, K., D. Laoui, C. Gysemans, M. Baeten, G. Stangé, J. Van den Bossche, M. Mack, D. Pipeleers, P. In't Veld, P. De Baetselier, and J. A. Van Ginderachter. 2010. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70: 5728-5739.
34. Tian, J., J. Ma, K. Ma, H. Guo, S. E. Baidoo, Y. Zhang, J. Yan, L. Lu, H. Xu, and S. Wang. 2013. b-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur. J. Immunol. 43: 1220-1230.
35. Noy, R., and J. W. Pollard. 2014. Tumor-associated macrophages: from mechanisms to therapy. [Published erratum appears in 2014 Immunity 41: 866.] Immunity 41: 49-61.
36. Mantovani, A., and P. Allavena. 2015. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 212: 435-445.
37. Bronte, V., and P. J. Murray. 2015. Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer. Nat. Med. 21: 117-119.
38. Qian, B. Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder, and J. W. Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
39. Germano, G., R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, M. Liguori, E. Erba, S. Uboldi, M. Zucchetti, F. Pasqualini, et al. 2013. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23: 249-262.
40. Ries, C. H., M. A. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, F. Rey-Giraud, L. P. Pradel, F. Feuerhake, I. Klaman, et al. 2014. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25: 846-859.
41. Beatty, G. L., E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
42. Rolny, C., M. Mazzone, S. Tugues, D. Laoui, I. Johansson, C. Coulon, M. L. Squadrito, I. Segura, X. Li, E. Knevels, et al. 2011. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19: 31-44.
43. Pyonteck, S. M., L. Akkari, A. J. Schuhmacher, R. L. Bowman, L. Sevenich, D. F. Quail, O. C. Olson, M. L. Quick, J. T. Huse, V. Teijeiro, et al. 2013. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19: 1264-1272.
44. Rodríguez-Prados, J. C., P. G. Través, J. Cuenca, D. Rico, J. Aragonés, P. Martín-Sanz, M. Cascante, and L. Boscá. 2010. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J. Immunol. 185: 605-614.
45. Ward, P. S., and C. B. Thompson. 2012. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21: 297-308.
46. Colegio, O. R., N. Q. Chu, A. L. Szabo, T. Chu, A. M. Rhebergen, V. Jairam, N. Cyrus, C. E. Brokowski, S. C. Eisenbarth, G. M. Phillips, et al. 2014. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513: 559-563.
47. Rogers, N. C., E. C. Slack, A. D. Edwards, M. A. Nolte, O. Schulz, E. Schweighoffer, D. L. Williams, S. Gordon, V. L. Tybulewicz, G. D. Brown, and C. Reis e Sousa. 2005. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22: 507-517.
48. Underhill, D. M., E. Rossnagle, C. A. Lowell, and R. M. Simmons. 2005. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood 106: 2543-2550.
49. Través, P. G., P. de Atauri, S. Marín, M. Pimentel-Santillana, J. C. Rodríguez-Prados, I. Marín de Mas, V. A. Selivanov, P. Martín-Sanz, L. Boscá, and M. Cascante. 2012. Relevance of the MEK/ERK signaling pathway in the metabolism of activated macrophages: a metabolomic approach. J. Immunol. 188: 1402-1410.
50. LeibundGut-Landmann, S., O. Gross, M. J. Robinson, F. Osorio, E. C. Slack, S. V. Tsoni, E. Schweighoffer, V. Tybulewicz, G. D. Brown, J. Ruland, and C. Reis e Sousa. 2007. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8: 630-638.
51. Goodridge, H. S., R. M. Simmons, and D. M. Underhill. 2007. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J. Immunol. 178: 3107-3115.
52. Hsu, Y. M., Y. Zhang, Y. You, D. Wang, H. Li, O. Duramad, X. F. Qin, C. Dong, and X. Lin. 2007. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat. Immunol. 8: 198-205.